Marshall Urist, EVP & Co-Head of R&I at Royalty Pharma plc (RPRX), sold 66,268 shares at $47.02 ($3.1M) on 2021-06-07, disclosed to the SEC on 2021-06-08.
Open-market sale of $3.1M RPRX by EVP & Co-Head of R&I. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.13 | 16,566 | $748K | 24.5% |
| 2 | $45.13 | 16,566 | $748K | 24.5% |
| 3 | $47.02 | 16,568 | $779K | 25.5% |
| 4 | $47.02 | 16,568 | $779K | 25.5% |
| Total | $46.08 avg | 66,268 | $3.1M | 100% |
| Filing → |
| RPRX | SELL | 2026-07-02 | $508K | — | Filing → |
| RPRX | SELL | 2026-06-25 | $502K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |